Please login to the form below
Xadago
This page shows the latest Xadago news and features for those working in and with pharma, biotech and healthcare.
FDA approves Newron's Parkinson's disease drug Xadago
Those on Xadago experienced more beneficial “on” time, when their symptoms were reduced, without troublesome uncontrolled involuntary movement (dyskinesia), compared to those receiving a placebo. ... Newron has divided up the commercial rights to
Latest news
-
Newron back on track for Xadago approval in US
Newron Pharma will not have to conduct any additional clinical trials for its Parkinson's disease drug Xadago in the US, setting up a new FDA filing in the coming weeks. ... The Italian pharma company's partner Zambon is already rolling Xadago (safinamide
-
Rare disease therapies head the ‘class of 2015’
neprilysin inhibitor. Novartis. USA. safinamide. Xadago. Parkinson's disease. MAO-B inhibitor. Newron Pharma.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- The UK’s new medicines pricing deal – opportunities and risks for pharma
- Biogen’s Aduhelm unlikely to get approval in Europe
PMHub
Mednet Group
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
